G-Rex^® Grant Tour

Supporting the Emily Whitehead Foundation

MADRID

Hear from leaders bringing hope to patients through advanced cell & gene therapies

Meet Dr. Alena Gros Vidal

Alena Gros Vidal is a Group Leader at the Tumor Immunology and Immunotherapy Group in the Vall d’Hebron Institute of Oncology (VHIO).Alena trained in Biology and obtained a PhD in Genetics in 2009 from the University of Barcelona. After that, she undertook a 7-year postdoctoral fellowship at the NCI with Steven A. Rosenberg, one of the pioneers in the field of Cancer Immunotherapy. In 2016 she was appointed to lead the Tumor Immunology and Immunotherapy Group at Vall d’Hebron Institute of Oncology (VHIO, Barcelona). For the last 15 years, her research has focused on understanding the native antitumor T-cell response in cancer patients and its molecular determinants to design more effective T-cell therapies for the treatment of solid cancers. Her scientific contributions to the cancer immunology and immunotherapy field are well recognized, as reflected in the citation of her work (49 publications, >11,000 citations, and H-index of 35; Google Scholar 2025). Her research has advanced the identification of biomarkers to detect and potentially exploit the personalized repertoire of neoantigen- and tumor-reactive lymphocytes residing in the tumor and in the peripheral blood of cancer patients. She also participated significantly in developing tools to better understand and exploit the native antitumor T cell response in cancer patients such as screening methods to detect, isolate, and clone tumor- and neoantigen-reactive TCRs from tumor-resident TIL and blood and to identify their cognate antigens. Her appointment at VHIO launched the Cell Therapy Program, currently one of the strategic focuses of the center. Within this program, her contributions have been instrumental in designing and translating personalized T-cell therapies at VHIO, including three ongoing clinical studies and two additional that were recently authorized by the Spanish Regulatory Agency (AEMPS). Her research has led to 10 patents and several licenses, underscoring the competitivity of her research program and their strength at translating potentially transformative new T cell therapies to patients, directly impacting patient lives.

Meet Dr. Begoña Diez Cabezas

Begoña Díez Cabezas is a postdoctoral researcher at the Biomedical Innovation Unit at CIEMAT (Madrid, Spain), where she focuses on the development of more accessible CAR-T cell therapies. Her work combines translational research and advanced therapy manufacturing to improve the scalability and affordability of CAR-T approaches. She has extensive experience in the GMP production of advanced therapy medicinal products and in the development of novel CAR-T strategies aimed at expanding patient access to these treatments.

Meet Dr. Núria Gavaldà

Núria Gavaldà is the Strategy Director of the Advanced Therapy Medicinal Products (ATMP) Manufacturing Platform at the Blood and Tissue Bank (BST) of Catalonia.The BST ATMP Platform develops and manufactures innovative advanced therapies within an academic environment, promoting scientific excellence and translational impact. It is an infrastructure designed to advance cell and gene therapies within the healthcare ecosystem, developing and manufacturing hMSCs, virus-specific T cells, tumour-infiltrating lymphocytes (TILs), CAR-T cells, and lentiviral vectors.She holds a PhD in Biology, a Postgraduate Degree in Pharmacovigilance from the University of Barcelona and has completed the Executive Program in Healthcare Institutions at IESE Business School.She worked as a Research Associate at Cardiff University (United Kingdom) and was later appointed Scientific Director at SOM Biotech, a Barcelona-based biotech company dedicated to drug repurposing. Between 2014 and 2023 she was the Director of Strategy at Vall d’Hebron Research Institute (VHIR), in Barcelona.

Meet Mr. Ignacio Nunez, M.Sc., MBB

Ignacio Nunez is a seasoned operator and manufacturing executive with deep expertise in biologics, cell and gene therapies, and complex GMP manufacturing systems. He has spent his career helping organizations translate breakthrough therapies into scalable, reliable operations.Most recently, Ignacio served as Chief Operating Officer of CellReady, where he led the company’s operational expansion in the cell and gene therapy space. He drove large-scale organizational and manufacturing transformations, delivering material reductions in capital expenditure and development timelines while strengthening GMP manufacturing, quality systems, and supply chain performance across collaborations with global biopharma, emerging biotech, academic institutions, investors, and CDMOs/CROs.Earlier, Ignacio contributed hands-on to the industrialization and commercialization of next-generation therapies, including some of the first FDA-approved cell and gene therapies. He founded BioExcellence to bring operator-led execution to clients—developing high-throughput manufacturing and operational excellence models adopted in the design and optimization of large-scale cell therapy production facilities.Ignacio holds B.S. and M.Sc. degrees in Chemical Engineering from the University of Granada and is a certified Lean Six Sigma Master Black Belt.

Global Resources, Madrid Innovation.

Join the coalition accelerating patient cures right here in Madrid.

Tackling Solid Tumors

Dive deep into 'The Last Frontier' of cancer therapy with pioneers from Vall d'Hebron Instititute of Oncology

State of CGT in Madrid

Engage with experts shaping the future of the Spain biotech ecosystem.

Network and Engage

Participate in the "Believe Bundle Creation" and support the Emily Whitehead Foundation’s mission to save lives.

Event Sponsors

R&D Systems — sponsor of the G-REX Grant Tour

Event Essentials

Prepare for a full day of innovation, networking, and impact.

G-Rex Grant Tour

If you're building the future of cell therapy - this is your place

Interested in Sponsoring?

Are you a provider of tools, technology, or services used in research, development, or manufacturing of cell and gene therapies?
Does your innovation pair nicely with G-Rex?
If yes, please consider sponsoring one, some, or all of the G-Rex Grant Tour events. Your sponsorship is a tax deductible donation to the Emily Whitehead Foundation.

G-Rex Grant Tour Raleigh (RTP)

G-Rex^® Grant Tour

Supporting the Emily Whitehead Foundation

MADRID, SPAIN

Coming to Madrid

The G-Rex Grant Program is a transformational initiative that culminated in the awarding of >300 G-Rex Grants and >$40M in resources and has resulted in a powerful coalition of organizations and individuals working to bring hope to cancer and autoimmune patients through adoptive cell and gene therapy.

In 2026, ScaleReady will host a series of events around the United States and Europe with the goals of:

The G-Rex Grant Tour will be co-produced by the Emily Whitehead Foundation (EWF) and all sponsorship fees will go directly to support the EWF mission “to support patients and caregivers affected by cancer and rare diseases, and advocate for all patients who can be treated with advanced therapies”.

Location & Date:

Be first to know when registration opens.

Sign up to receive updates on available seats, event timing, and the growing list of speakers for the G-Rex® Grant Tour 2026.

G-Rex Grant
Tour 2026

LEARN MORE

G-Rex^® Grant Tour

Supporting the Emily Whitehead Foundation

HOUSTON

A recap of the speaker presentations and panel discussions from the Houston event.

Event Sessions

Catch up on all the insightful presentations.

Meet Dr. Ann Leen

Dr. Leen is an immunologist and a Professor of Pediatrics at Baylor College of Medicine (BCM). She has an extensive background developing and clinically testing a variety of novel immune-based therapies to treat patients with post-transplant viral infections and malignancies including lymphoma, multiple myeloma, leukemia, breast and pancreatic cancer. Dr. Leen was part of the Baylor team to first optimize the G-Rex for T cell production preclinically and for advancing the platform to the GMP for clinical manufacturing, and this contribution is reflected in her being a named co-inventor on multiple G-Rex patents.Over the past 20+ years at BCM Dr. Leen has served as a PI on numerous clinical trials using cell therapies for patients,many of which were produced using the G-Rex. Overall, Dr. Leen is a named inventor on 32 patents/patent applications and has co-founded two companies AlloVir and Marker Therapeutics. She has served as a primary mentor for summer students, graduate students, post-doctoral fellows and clinical fellows. In 2011 she was awarded TXCH Faculty Recognition Award for Teaching Excellence and in 2018 was recognized by the BCM graduate school for 2018 for her contribution to graduate student training.

Meet Dr. Cassian Yee

Dr. Yee is an oncologist, immunologist and endowed Professor in the Division of Cancer Medicine at MD Anderson Cancer Center where he is also Director of the Solid Tumor Cell Therapy Program. His lab pioneered a cell therapy modality known as Endogenous T Cell therapy that provided first clinical proof-of-concept of T cell memory, antigen- spreading, checkpoint inhibitor synergy, and years-long persistence of transferred T cells mediating durable complete responses without a requirement for lymphodepletion or high-dose IL-2. As a physician-scientist, his research converges multidisciplinary approaches in bioengineering, metabolism, epigenetics and molecular immunology into enabling technologies that render adoptive cell therapy more effective and accessible as a treatment modality for patients with common and rare cancers. He is founder of an AI startup and TCR-T cell therapy company (Mongoose Bio) with assets developed in Yee Lab focused on solid tumors, leveraging one of the largest immunopeptidomes established from MS-defined datasets. His latest project is a NASA-funded initiative to take T cells to the International Space Station.

Meet Dr. Marie-Andrée Forget

Marie-Andrée Forget, PhD, is a Principal Scientist at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. For the past three years, she has led the TIL Therapy Process Development group, enabling five INDs and six IND amendments for academic and biotech partners. Her team developed the CTMC Manufacturing TIL platform, designed to accelerate development while reducing manufacturing time and cost for non-engineered TIL as well as viral-based and non-based engineered TIL products. Before joining CTMC, Marie was recruited to MD Anderson as a postdoctoral research fellow co-mentored by Drs. Laszlo Radvanyi and Lawrence Cooper to improve the TIL manufacturing process. This included adoption of the G-Rex device in manufacturing, development of a new feeder platform, and implementation of retroviral engineering for TIL expansion. After being promoted to Scientist in charge of manufacturing production, including GMP TIL production, Marie co-authored over 45 peer-reviewed papers and two book chapters.Marie began her career in a diagnostic laboratory before earning her MS and PhD in immuno-oncology from the University of Montreal, where she studied TIL and tumor-specific T-cell expansion and tumor antigen validation for immunotherapy.

Meet Monica Avila

Monica Avila is a highly accomplished CMC Quality professional with over 15 years of industry experience in biotech. Known for her proven expertise in driving quality and compliance excellence, Monica has held senior leadership roles overseeing critical drug development activities, including scale-up, process development, and clinical stage manufacturing.She currently serves as Sr. Director, CMC Alliance and Project Management at Cellenkos Inc., where she provides leadership on all drug development and manages the company’s CMC outsourcing activities. Monica has successfully led the tech transfer of numerous projects to GMP manufacturing and has co-authored technical and regulatory documents for multiple IND submissions.

Meet Dr. Austin Bigley

Austin Bigley serves as the Vice President of Manufacturing Science and Technology at Indapta Therapeutics. With a distinguished career focused on spaceflight immunology and cancer immunotherapy utilizing natural killer (NK) cells, Austin brings extensive research expertise in exercise and spaceflight immunology, complemented by a robust publication record. His work notably explores how Cytomegalovirus (CMV) infection influences NK-cell activity against hematologic malignancies.Austin’s primary research objective is to elucidate the mechanisms by which exercise, spaceflight, and CMV infection impact NK-cell phenotype, cytotoxicity, proliferative capacity, and longevity. This research aims to develop effective ex vivo NK-cell expansion protocols to produce clinical-grade NK-cell products for use in cancer and anti-viral immunotherapy.Throughout his academic tenure, Austin has developed proficiency in a range of technical skills, including cell culture techniques, cellular expansion methods, cytotoxicity and functional assays, and flow cytometry. These skills have significantly contributed to his numerous publications in prestigious peer-reviewed journals. Moreover, he is the inventor of the g-NK cell expansion method currently utilized by Indapta Therapeutics and has developed several quality control potency and phenotypic identity assays.

Meet Dr. Mamta Kalra

Mamta Kalra joined Immatics in 2016 and is responsible for manufacturing process and analytical development for autologous and allogeneic ACT programs.Mamta has ~15 years of experience in the field of cell and gene therapy. She started with adoptive T-cell therapy of EBV-related cancers and other solid tumors at Center for Gene Therapy, Baylor College of Medicine. She was instrumental in process and analytical development activities including process optimization, potency testing of products and immune-monitoring for multiple adoptive T-cell therapy trials. Upon joining Immatics, she led process development for ACTengine program and gradually expanded her contributions to encompass diverse activities under analytical development including viral vector. In addition to manufacturing advancements, she also promoted innovation leading to product and platform development for various next-generation TCR-T programs.Mamta Kalra holds a PhD in Immunology from Postgraduate Institute of Medical Education and Research, India and a postdoctoral training in adoptive T-cell therapy from Center for Cell and Gene Therapy at Baylor College of Medicine.

Meet Mr. Peter Gelinas

Mr. Gelinas is a biotechnology executive with more than 15 years of experience leading CMC and technical operations in cell and gene therapy companies. He has advanced programs from Phase I through commercialization, building global manufacturing networks, driving regulatory filings, and leading high-performing technical organizations. Most recently, Mr. Gelinas served as Senior Vice President of CMC (chemistry, manufacturing and controls) at AffyImmune Therapeutics, where he led strategy for a first-in-class autologous CAR-T therapy. Previously, he was Vice President and Head of Manufacturing & Technical Operations at ElevateBio, overseeing operations across a broad portfolio of autologous and allogeneic cell and gene therapies. Earlier, in senior leadership roles at bluebird bio, Peter played a key role in bringing the first-in-class gene therapies SKYSONA™ and ZYNTEGLO™ to market, leading process validation (PPQ), global technology transfers, and regulatory submissions to secured FDA and EMA global approvals.

Meet Ignacio Nunez, M.Sc., MBB

Meet Dr. Verena Kallhoff

Dr. Verena Kallhoff is the Senior Director of Global Life Sciences at the Greater Houston Partnership, where she leads strategic initiatives to grow and strengthen the region’s life sciences and biotechnology ecosystems. She works closely with local, state, national, and international stakeholders to support innovation, attract investment, and assist companies seeking to relocate or expand in the Greater Houston area.Prior to joining the Partnership, Dr. Kallhoff served as Vice President of Omics and Precision Medicine at Equideum Health, a health tech startup. She also held multiple leadership roles at The University of Texas at Austin, including directing The WorkSpaces at Texas Health CoLab, the innovation hub at Dell Medical School. There, she worked with innovators and startups commercializing their technology and developed and led programs to foster regional innovation. In response to the COVID-19 pandemic she became a co-founder of TEXGHS—the Texas Global Health Security Consortium.Earlier roles include positions at Harris Health System and Houston Methodist Research Institute, where she was the Managing Director of CyBHOR, an Industry/University Cooperative Research Center funded by the National Science Foundation. Dr. Kallhoff earned her Ph.D. in Molecular and Human Genetics from Baylor College of Medicine and an MBA from the University of Houston–Clear Lake.

Meet Dr. Ferran Prat

Dr. Ferran Prat serves as the Chief Commercial Officer at BostonGene, where he leads the company’s commercial strategy, including sales, marketing and business development. With deep expertise in business development across the healthcare, pharmaceutical and biotechnology sectors, Dr. Prat brings extensive experience in licensing, strategic partnerships, regulatory affairs, operations and program management.Before joining BostonGene, Dr. Prat was Senior Vice President of Research Administration and Industry Relations at The University of Texas MD Anderson Cancer Center. In this role, he led major collaborations with the biopharma industry, translating cutting-edge science into clinical applications and positioning MD Anderson as a leading center for industry engagement.Earlier in his career, Dr. Prat held leadership roles at Alere Inc. (now part of Abbott Laboratories) and worked as a management consultant at McKinsey & Company. He earned his PhD in Organic Chemistry from the University of California, Los Angeles and a JD from the University of San Diego School of Law.

Meet Dr. Michael Dilling

Michael Dilling is Executive Director of Commercialization at the BCM Innovation Institute, the integrated commercialization team at Baylor College of Medicine (BCM) - a nationally recognized biomedical research institution and the only private medical school in the Southwestern U.S.BCM leads all Texas-based institutions in NIH research funding and hosts top-ranked departments. Under Dilling’s leadership, BCMII builds strategic commercial partnerships that help translate biomedical discoveries into products and services that benefit patients and support BCM’s academic mission. Over the past five fiscal years, the team has completed 250+ licensing transactions and negotiated industry-sponsored research and services contracts valued at over $95 million.Dilling oversees the BCMII team of six technology management professionals, a compliance expert, and a team of three financial professionals. With over 25 years of experience in academic technology commercialization, he has negotiated or guided the negotiation of hundreds of agreements between BCM and commercial partners. He also teaches the graduate course “Commercialization of Biomedical Technologies”, covering IP, startup formation, fundraising, and product development.An active member of the Association of University Technology Managers (AUTM), Dilling contributes to its Mentorship Committee and helped develop new mentorship tools. He holds a Ph.D. in Genetics from Texas A&M (1993), an MBA from the University of Memphis (1999), and completed postdoctoral work at St. Jude Children’s Research Hospital. He joined BCM in 2000.

Meet Chris White

Chris White is a cancer survivor, patient advocate, and national speaker whose personal journey helped shape one of the most significant milestones in solid tumor cancer treatment. He is the final patient ever dosed in the phase 2, cohort 4 clinical trial that led to the first FDA approved advanced cellular therapy for any solid tumor cancer in history. This therapy is known as Lifileucel or by its commercial name, AMTAGVI.Chris is the last of the 153 total patients treated in this groundbreaking study. He is one of only 12 participants in the trial with mucosal melanoma and one of just 6 from that group to achieve a clinical response. His outcome is particularly remarkable given that he entered the trial with stage 4 disease, metastasis to major organs and his brain, and no remaining standard treatment options.On January 15, 2020, Chris received his TIL infusion followed by all six recommended doses of IL 2. That was the final treatment he ever required. Within six weeks his tumors had reduced by an estimated 50 to 60 percent. Within nine months his scans showed a complete metabolic response.The accelerated approval of AMTAGVI in February 2024 marked a historic shift in cancer care and opened the door for additional biotherapeutics and advanced cellular therapies for solid tumors. Since solid tumors represent roughly 90 percent of all cancer diagnoses and statistics show that about 40 percent of people will face cancer in their lifetime, expanding access to options that preserve both quality and quantity of life is critical.Chris now uses his voice and experience to educate and empower patients, caregivers, clinicians, and researchers. By sharing his story, he provides clarity, perspective, and hope for everyone navigating cancer or exploring the promise of advanced therapies.

Panel Discussions

Business Roundtable

A discussion about the CGT business with Dr. Michael Dilling, Dr. Ferran Prat, Dr. Verena Kallhoff and Mr. Ignacio Nunez

Solid Tumors, The Last Frontier

A panel discussion with Dr. Ann Leen, Dr. Cassian Yee, and Dr. Marie-Andree Forget

Image Gallery

Event Sponsors

G-Rex is the superior and market leading platform for cell therapies with solid tumor indications

Two adoptive cell therapy approaches for solid tumors and epithelial cancers have received FDA approval (Iovance Biopharmaceutical’s AMTAGVI^® and Adaptimmune’s TECELRA^® and many more under clinical development are showing promise. G-Rex has long been the gold standard in the research, development, and manufacturing of these innovation approaches.

G-Rex & TCR-T cell therapy

TCR-T cell therapy leaders choose G-Rex

Dr. Cassian Yee

MD Anderson Cancer Center

Listen to Dr. Cassian Yee from M.D. Anderson Cancer Center (an early adopter of G-Rex) give a masterclass on how TCR-T cell therapy brings hope to cancer patients.

G-Rex & Tumor Infiltrating Lymphocyte (TIL) therapy

TIL therapy leaders choose G-Rex

One of the most pivotal moments in the G-Rex’s history was the adoption and implementation of G-Rex at the National Cancer Institute’s Surgery Branch, led by the legendary Dr. Steven A Rosenberg.

The NCI Surgery Branch continues to utilize G-Rex to this today for their various adoptive cell therapy programs to bring hope to solid tumor cancer patients.

Dr. Marie-Andrée Forget

CTMC

Listen to Dr. Marie-Andree Forget from CTMC chronicle the co-evolution of TIL therapy and G-Rex.

G-Rex & Tumor-Associated Antigen (TAA) T cell therapy

T cell therapy leaders choose G-Rex

Dr. Ann Leen

Baylor College of Medicine

Listen to Dr. Ann Leen from the Baylor College of Medicine describe a recent breakthrough in pancreatic cancer through the use of a polyclonal T cell product, powered by G-Rex.

G-Rex for CAR-T cell therapy

G-Rex is the superior and market leading platform for developers of CAR-T cell therapy

G-Rex devices have been used in the development and manufacturing of CAR-T cell therapies for over 10 years. Notable early adopters include Baylor College of Medicine’s Cell & Gene Therapy, NCI Surgery Branch, and the Seattle Children’s Research Institute. Moreover, G-Rex is used in commercial production of the most successful, profitable, and accessible CAR-T cell therapy on the market.

Qualifying a reduced scale model

The G-Rex’s linear scalability can be utilized to qualify your manufacturing process in a “reduced scale model”.
Reduced scale models can be used throughput preclinical and clinical development, including late stage CMC development, BLA preparation, and post-approval program management.
Reduced scale models enable you to do more with less.
Scaling down (1/50-1/250th) the size of each replicate conserves resources.
Scaling out replicates (through G-Rex multiwell plates) increases knowledge acquisition, enhances process understanding and characterization, and drives continuous improvement.

Qualifying a multi-product ballroom

Many G-Rex devices can fit inside of one standard incubator, offering unparalleled density and throughput in drug product manufacturing.
Regulatory bodies (FDA, EMA, NMDA, etc.) will absolutely allow many drug products to be manufactured concurrently within the same cleanroom environment, so long as one demonstrates process control – specifically chain of identity, segregation, and traceability.
Qualifying a multi-product ballroom unlocks flexible, modular, and scale for resource conscientious and responsible CGT manufacturers.
Throughput will dramatically increase without commensurate increases in manufacturing overhead costs (the largest cost driver) – leading to sharp reductions in drug product cost.

G-Rex is the most versatile platform technology for manufacturing CAR-T cell therapies

Contrary to popular belief, a G-Rex device can (and should) be used to perform the majority of the core unit operations in canonical CAR-T cell production: Purification, Activation, Transduction, Expansion, and Concentration.

Chemical Process Flow

Decentralized & Point of Care CAR-T cell manufacturing with G-Rex

The need for space-efficient, high-throughput manufacturing is a requirement of all modes of CAR-T cell therapy production, including distributed production. It matters not if a developer chooses to manufacture from one centralized facility or many de-centralized facilities, high-throughput manufacturing will be a common denominator. Because of this, many institutions leading the charge on decentralized manufacturing of CAR-T cell therapies have turned to G-Rex. One of the leading developers and manufacturer’s of localized CAR-T cell therapy production is Caring Cross.

Caring Cross is a 501(c)(3) non-profit focused upon accelerating the development and implementation of advanced medicines like CAR-T cell and stem cell gene therapies. In partnership with like-minded stakeholders, Caring Cross develops and deploys technologies, systems, and therapeutic candidates that improve the affordability and accessibility of these potentially life-saving therapies for all patients in need, everywhere.

As shown, G-Rex is the bioreactor of choice for Caring Cross as a way “to build a low-cost CAR-T point-of-care production pipeline, at scale, that can be implemented in a dedicated clean-room or in a mobile clean-room setting”.

Fully-closed production of CAR-T therapies using G-Rex bioreactors

G-Rex bioreactors are available in fully closed formats with validated sterile fluid paths. Not only does this enable manufacturing outside of the biosafety cabinet in less controlled clean rooms, it also enables a multi-product ballroom concept.

Closed system G-Rex bioreactors have the smallest footprint in the industry and this enables the most economical use of space.
Fluid can be inoculated into standard G-Rex through simple sterile tube welding and heat sealing. Future directors of G-Rex product development efforts will seek to eliminate tube welding and sealing altogether in favor of sterile connectors.

1 Gas Permeable Membrane
2 Polycarbonate Shell (Vessel)
3 Polypropylene Multi-Port Cap
4 Vent Filter (0.2 µm)
5 Sample Line Tubing
6 MicroClave® Connector
7 Reduction Line Tubing
8 PVC Weldable Reduction Line
9 Harvest Line Tubing

Moreover, it has recently been demonstrated that complete elimination of the biosafety cabinet can be achieved using clever new products from our collaborators at Biolife Solutions.

Eliminating the biosafety cabinet is a critical achievement that removes bottlenecks in manufacturing, dramatically streamlines the flow of the drug substance through the final assembly line, directly increasing throughput and lowering cost of goods. This marks a major step forward towards increasing global patient access to advanced therapies by lowering the burden to implementing highly efficient G-Rex based CGT production.

Are you ready to scale?

Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.

G-Rex for Natural Killer (NK) and CAR-NK cell therapies.

G-Rex devices are routinely used in the clinical (GMP) production of Natural Killer cells, both unmodified and gene-modified (CAR or TCR-NK), because of their simplicity, scalability, and robustness. Titans of NK cell therapy, including pioneers at Baylor College of Medicine and the M.D. Anderson Cancer Center, have used G-Rex to produce therapeutic NK cell drug product for over a decade.

NK cell therapy leaders choose G-Rex

Dr. Austin Bigley

Indapta Therapeutics

For decades the titans of NK cell therapy have chosen G-Rex as their preferred platform. Hear from Dr. Austin Bigley, VP of R&D at Indapta Therapeutics, present at the Texas Medical Center regarding how Indapta Therapeutics is bringing hope to cancer patients through G-Rex and natural killer cell therapy.

Process Development & Manufacturing

Developers like Senti Bio leverage the G-Rex’s linear scalability to efficiently scale up/down and scale out.

See the poster Senti presented highlighting a linearly scalable CAR-NK cell therapy process.

Investigators like those at the University of Minnesota leverage the G-Rex’s simplicity and robust expansion capacity to efficiently produce large quantities of high-quality CAR-NK cells

See the manuscript illustrating a non-viral CAR-NK cell manufacturing process.

G-Rex® for γδ T cell therapy

G-Rex® for Natural Killer T (NKT) cell therapy

NKT cell therapy leaders choose G-Rex.

Leading investigator Dr. Lili Yang and her team at UCLA describe in a recent Nature Biotech article how to differentiate and expand CAR-NKT cells with high-yield, purity, antitumor efficacy, and persistence using G-Rex devices.

Dr. Leonid Metelitsa, a pioneer of NKT cell therapy at Baylor College of Medicine, has published extensively on the autologous and allogeneic use of NKT cell therapy to treat a variety of cancers. In a recent Molecular Therapy article, Dr. Metelitsa and his team describe how to generate better NKT cells through the use of IL-18. At the heart of the their NKT cell culture protocol is G-Rex.

G-Rex Grant Tour Minneapolis

G-Rex^® Grant Tour

Supporting the Emily Whitehead Foundation

MINNEAPOLIS

Coming to Minneapolis

In 2026, ScaleReady will host a series of 12-events around the United States with the goals of:

Event Sponsors

Be first to know when registration opens.

Sign up to receive updates on available seats, event timing, and the growing list of speakers for the G-Rex® Grant Tour 2026.

G-Rex Grant
Tour 2026

LEARN MORE

G-Rex Grant Tour Phoenix

G-Rex^® Grant Tour

Supporting the Emily Whitehead Foundation

PHOENIX

Coming to Phoenix

In 2026, ScaleReady will host a series of 12-events around the United States with the goals of:

Event Sponsors

Be first to know when registration opens.

Sign up to receive updates on available seats, event timing, and the growing list of speakers for the G-Rex® Grant Tour 2026.

G-Rex Grant
Tour 2026

LEARN MORE

G-Rex Grant Tour New York

G-Rex^® Grant Tour

Supporting the Emily Whitehead Foundation

NEW YORK

Coming to New York

In 2026, ScaleReady will host a series of 12-events around the United States with the goals of:

Event Sponsors

Be first to know when registration opens.

Sign up to receive updates on available seats, event timing, and the growing list of speakers for the G-Rex® Grant Tour 2026.

G-Rex Grant
Tour 2026

LEARN MORE

1 2 3 4

G-Rex® Grant Tour

Supporting the Emily Whitehead Foundation

MADRID

Location

Date

Event Agenda

Register for Event

Hear from leaders bringing hope to patients through advanced cell & gene therapies

Meet Dr. Alena Gros Vidal

Meet Dr. Begoña Diez Cabezas

Meet Dr. Núria Gavaldà

Meet Mr. Ignacio Nunez, M.Sc., MBB

Global Resources, Madrid Innovation.

Join the coalition accelerating patient cures right here in Madrid.

Tackling Solid Tumors

State of CGT in Madrid

Network and Engage

Event Sponsors

Event Essentials

Mark your calendar

FullAgenda

Registerfor event

G-Rex Grant Tour

If you're building the future of cell therapy - this is your place

G-Rex® Grant Tour

Supporting the Emily Whitehead Foundation

MADRID, SPAIN

Coming to Madrid

Location & Date:

Be first to know when registration opens.

Sign up to receive updates on available seats, event timing, and the growing list of speakers for the G-Rex® Grant Tour 2026.

G-Rex Grant Tour 2026

G-Rex® Grant Tour

A recap of the speaker presentations and panel discussions from the Houston event.

Event Sessions

Meet Dr. Ann Leen​

Meet Dr. Cassian Yee

Meet Dr. Marie-Andrée Forget​

Meet Monica Avila

Meet Dr. Austin Bigley

Meet Dr. Mamta Kalra

Meet Mr. Peter Gelinas

Meet Ignacio Nunez, M.Sc., MBB

Meet Dr. Verena Kallhoff

Meet Dr. Ferran Prat

Meet Dr. Michael Dilling

Meet Chris White

Panel Discussions

Business Roundtable

A discussion about the CGT business with Dr. Michael Dilling, Dr. Ferran Prat, Dr. Verena Kallhoff and Mr. Ignacio Nunez

Solid Tumors, The Last Frontier

A panel discussion with Dr. Ann Leen, Dr. Cassian Yee, and Dr. Marie-Andree Forget

Image Gallery

Event Sponsors

G-Rex is the superior and market leading platform for cell therapies with solid tumor indications

G-Rex & TCR-T cell therapy

TCR-T cell therapy leaders choose G-Rex

G-Rex & Tumor Infiltrating Lymphocyte (TIL) therapy

TIL therapy leaders choose G-Rex

G-Rex & Tumor-Associated Antigen (TAA) T cell therapy

T cell therapy leaders choose G-Rex

G-Rex for CAR-T cell therapy

G-Rex is the superior and market leading platform for developers of CAR-T cell therapy

Qualifying a reduced scale model

Qualifying a multi-product ballroom

G-Rex is the most versatile platform technology for manufacturing CAR-T cell therapies

Decentralized & Point of Care CAR-T cell manufacturing with G-Rex

Fully-closed production of CAR-T therapies using G-Rex bioreactors

Are you ready to scale?

G-Rex for Natural Killer (NK) and CAR-NK cell therapies.

NK cell therapy leaders choose G-Rex

Process Development & Manufacturing

G-Rex® for γδ T cell therapy

G-Rex® for Natural Killer T (NKT) cell therapy

NKT cell therapy leaders choose G-Rex.

G-Rex® Grant Tour

Supporting the Emily Whitehead Foundation

MINNEAPOLIS

Coming to Minneapolis

Event Sponsors

G-Rex^® Grant Tour

Full
Agenda

Register
for event

G-Rex^® Grant Tour

G-Rex Grant
Tour 2026

G-Rex^® Grant Tour

Meet Dr. Ann Leen

Meet Dr. Marie-Andrée Forget

G-Rex^® Grant Tour

G-Rex Grant
Tour 2026

G-Rex^® Grant Tour

G-Rex Grant
Tour 2026

G-Rex^® Grant Tour

G-Rex Grant
Tour 2026